Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 2 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Head & Neck 3CNS 3Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 347Paclitaxel 309Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 176Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 112pembrolizumab 112Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 65Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Protons × Breast × Clear all
NCT01245712 2026-05-01

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡